Clinical Applications

Platform Overview: PRIMABS™-Dx Assay Workflow

PRIMABS-Dx measures baseline mitochondrial priming and ex vivo treatment-induced shift scores using standard clinical formats including flow cytometry and fixed-tissue immunohistochemistry. The platform is designed for seamless integration into existing laboratory infrastructure.

Sample Input

Ficoll purified and fixed peripheral blood or bone marrow biopsies; fixed solid tumor tissues (FFPE)

PRIMABS Processing

Standardized antibody staining and quantitative detection protocols

Predictive Output

Quantitative priming metrics and actionable treatment recommendation reports

PRIMABs recognized conformational epitopes on intracellular BCL-2 PPIs. Intracellular staining with PRIMABs on Ficoll-purified patient biopsies. Flow cytometry readouts are assessed for correlation to patient response to treatment. Schematic made using BioRender.

Methodology/Advantages

PRIMABS™‑Dx method

Why it matters for clinics and pharma

Measures BCL‑2 family PPIs defining mitochondrial priming using conformation‑specific PRIMABS antibodies in fixed or viably frozen samples

Uses short ex vivo drug exposure followed by priming readout and a “PRIMABS™ Shift Score.

Provides a surrogate functional readout of the final apoptosis checkpoint, downstream of diverse oncogenic pathways.

Works on real‑world biopsies; no fresh tissue requirement; fits standard clinical lab workflows (flow cytometry, IHC).

Supports PD studies, dose/regimen selection, and identification of resistance mechanisms in trials.

Complements genomic profiling, captures convergence of multiple targets on cell‑death commitment.

Clinical Applications: AML and Multiple Myeloma

AML PRIMABS-Dx

Flow cytometry assay on peripheral blood or bone marrow identifies priming patterns and predicts response to venetoclax-based regimens

Myeloma Assay

Identifies biomarker algorithms for standard-of-care combinations with existing and investigational agents

Custom Development

Platform available for custom CLIA assay development with pharmaceutical partners and clinical trial sponsors

PRIMABS™: Scientific Validation

Published, Peer‑reviewed studies at Eutropics have shown that PRIMAB readouts quantitatively correlate with BH3‑mimetic sensitivity and with muktiple targeted and chemo therapies.

Studies from Eutropics and various other labs using functional assays, including BH3 profiling, have shown that BCL‑2 family dependence and mitochondrial priming dynamics can correlate to therapeutic response across malignancies. This work has developed the paradigm and provided insights for clinical translation of PRIMABS‑Dx as a predictive and pharmacodynamic biomarker platform.